Friday, 21 Sep 2018

You are here

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

Based on data showing worse stroke outcomes in the face of high IL-6 and C-reactive protein (CRP) levels, researchers sought to assess whether control of inflammation post-CVA would limit cerebral ischemia and improve outcomes after ischemic stroke. 

A double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous anakinra (100 mg given twice daily for 3 days) was initiated within 5 hours of ischemic stroke onset.  The primary outcome was difference in concentration of log(interleukin-6) as area under the curve to day 3. Secondary outcomes included the 3-month stroke outcome assessed by modified Rankin Scale.

A total of 80 patients (mean age, 72 years) were enrolled and 73% received intravenous thrombolytic therapy. Patients were then treated with either placebo or anakinra bid for 3 days.  After 3 days the anakinra patients had significantly lower plasma interleukin-6 (P<0.001) and plasma C-reactive protein (P<0.001) levels.

Despite being well tolerated with no safety concerns, anakinra lowered the modified Rankin Scale, but this was not significant (OR=0.67; (0.29–1.52), P=0.34).

These insufficient 3 mos clinical outcomes may relate to the relatively short duration of anakinra therapy and other factors.  Yet these data suggest the potential interplay between inflammation (IL-1) and tissue damage from thrombotic events. 

These data follow a recent Lancet report of the CANTOS study showing cannakinumab (IL-1 inhibition) significantly lower rate of recurrent cardiovascular events (in high-risk CV patients); and at the same time reduce the rate of total cancer deaths, especially lung cancer. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.

Treatment Preferences in Still’s Disease

In July 2018, RheumNow launched a “Live Vote” survey of US and non-US rheumatologists that asked how they diagnose and treat systemic juvenile idiopathic arthritis (sJIA), also known as “Still’s disease”. It appears that many prefer to start therapy with an IL-1 inhibitor, after a course of steroids and MTX/DMARD. Yet, these findings suggest there are significant unmet needs in the diagnosis and management of sJIA patients.